Coral Gables, FL-based Catalyst Pharmaceuticals , Inc. (NASDAQ:CPRX), a $2.69 billion market cap biopharmaceutical company that has delivered an impressive 54% return to shareholders over the past ...

This was the stock's second consecutive day of losses.

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

CORAL GABLES, Fla., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced its inclusion in Forbes' esteemed list of America's Most ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 11.63% ...

For Full Prescribing and Safety Information for FIRDAPSE, please visit www.firdapse.com.

Shares of Catalyst Pharmaceuticals Inc. CPRX rose 1.32% to $22.21 Monday, on what proved to be an all-around mixed trading ...

Catalyst Pharmaceuticals (NASDAQ:CPRX – Get Free Report) had its price target raised by HC Wainwright from $30.00 to $35.00 ...

Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) recently disclosed in an 8-K filing with the Securities and Exchange Commission on January 13, 2025, that the company has posted a corporate presentation ...

Catalyst Pharmaceuticals, Inc. announced that its sub-licensee, DyDo Pharma, has launched FIRDAPSE® (amifampridine) Tablets 10 mg in Japan, aimed at improving muscle weakness in patients with ...